anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the reported annual recurrence rate in NVAF and previous stroke patients in the "real-world" is not low even with appropriate antithrombotic treatment; 8.6% in patients with "guideline adherent" antithrombotic therapy and around 5% in patients treated with anticoagulant therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent task.

Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some retrospective studies showed a beneficial effect of CA for stroke prevention using age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve survival or prevent heart failure development in patients with AF. However, the effect of CA for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke for survival or developing heart failure has not been evaluated in a prospective randomized trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF with a history of cerebral infarction: a group receiving standard medical therapy (control group) and a group receiving standard medical therapy plus CA (CA group).
1513742 2,3,6,7 - Tetrahydro - 5H - pyrrolo- (1,2 - a)imidazoles IMPERIAL CHEMICAL INDUSTRIES Ltd 16 Jan 1976 [31 Jan 1975] 4303/75 Heading C2C Novel Compounds I and their acid addition salts in which R1, R2, R3 and R5 are H or C 1-4 alkyl, R4 is H or C 1-4 alkyl and Ar is optionally substituted aryl or Ar represents aryl which has a substituent adjacent the linking position which substituent together with R4 represents C 1-3 alkylene and the aryl moiety may be further substituted are prepared by cyclizing a Compound II, III, IV, V, VI or VII. in which X is Hal, OH or a sulphonyloxy radical or hydrolysis and decarboxylation of an ester VIII or IX in which R6 is C 1-6 alkyl and if desired (a) reducing NO 2 to NH 2 or acylating NH 2 in a compound in which Ar bears such substituents (b) forming a salt or (c) resolving a racemic compound into its enantiomers. Compounds II, III or IV are prepared by reacting a Compound X where Z is OEt with a compound XI or a Compound XIa Compounds X are prepared by reacting a pyrrolidone with EtOH under acidic conditions. Compounds XII are prepared by methods disclosed in Specification 1,140,188. Compounds V are prepared by reacting pyrrolidone XII with a Compound XI or XIa or when R1=H with X-CHR2-CN followed by reduction. Compounds I have anti-hypertensive activity and may be used in pharmaceutical compositions for administration orally or parenterally. The compositions may further contain vasodilators (glyceryl nitrate, pentaerythritol tetranitrate and isosorbide dinitrate); diuretics (chlorothiazide), other hypotensive agents (reserpine, bethanidine and guanethidine) and #-adrenergic blocking agents (propranolol).
Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery. In recent years there has been an evolution in management approach and pharmacologic options for treatment. As a result, there is increased focus on the efficacy and safety of these agents. We provide a historical perspective, review of recent studies on anti-obesity medication outcomes showing efficacy, potential side effects and promising therapies in development.
Topiramate is a medication that is approved for the treatment of seizures. In accordance with International guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety. This is an open-label, multi-center observational safety study to collect safety information for oral topiramate given in addition to other medications for 3 types of seizures in adults and in children aged 2 years and older.The 3 seizures types are focal epilepsy, LENNOX-GASTAUT syndrome epileptic seizures and generalized tonic-clonic seizures. Patients whose previous treatment for seizures (one or more antiepileptic drugs) has been judged by their physician to be non-satisfactory will receive 6 months of treatment with topiramate in addition to other antiepileptic medication as prescribed by their physician. Topiramate will be given at low doses initially and gradually increased as necessary to control seizure activity in accordance with Summary of Product Characteristics (SmPC). Patients will be asked to keep a diary of adverse events and seizure activity. Safety evaluations (incidence of adverse events, physical examinations, vital signs and laboratory tests) will be performed throughout the study per investigators usual standard of care. At the end of the study, the treating physician may continue treatment with topiramate and other medication as appropriate. The study hypothesis is that topiramate given in combination with other antiepileptic medications will be effective in achieving and maintaining control of seizure activity and is well-tolerated. 225 adult patients and children aged 2 years or older will be enrolled in the study. Study participants should demonstrate focal epilepsy or epileptic seizures of the LENNOX-GASTAUT syndrome or generalized tonoclonic seizures, who have undergone treatment with one or more antiepileptic drugs and whose treatment should be judged by the investigator as non-satisfactory. Observational study - No investigational drug administered.
The isolated proteins kalinin and k-laminin are disclosed to provide adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes of human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 410-495 kDa and exists in a cell-associated form (about 495 kDa) and two medium-associated forms (about 460 and 410 kDa, respectively). The BM165 epitope is located on the 165-kDa and 200 kDa subunits. Kalinin has a rotary-shadow image revealing an asymmetric rod 107-nm long having two globules at a first end and a single globule at an opposing end. The k-laminin adhesion molecule is an isolated heterotrimeric laminin variant that has a molecular weight of about 650 kDa and separates on western blots into first and second fragments that are similar to the B1 and B2 fragments of laminin. K-laminin also includes a third fragment of 190 kDa that is not immunoreactive with monoclonal antibodies 1F5, 11D5 and 4C7, but is immunoreactive with a monoclonal antibody BM165. Kalinin and k-laminin are preferably covalently associated. A method is also disclosed for improving adhesion of transplanted keratinocytes to an underlying substrate, such as the human dermis, by optimizing production of kalinin from cultured keratinocytes, or by providing an exogenous source of kalinin between the keratinocytes and substrate.
Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
External oblique intercostal plane block (EOIPB) was reported by Elsharkawy et al . It is a novel block, which has been described as an important modification of the fascial plane blocks that can consistently involve the upper lateral abdominal walls. In comparison to quadratus lumborum block (QLB) and erector spinae plane block (ESPB) , EOIPB has the benefit of being performed when the patient is supine. It also has an advantage over serratus intercostal plane block (SIPB) in that it produces greater analgesia throughout the midline of the abdomen.

Dexmedetomidine is used for sedation in patients admitted to the intensive care unit (ICU). Dexmedetomidine is a selective alpha 2- adrenoceptor agonist possessing sedative, anxiolytic, and analgesic properties without the development of respiratory depression . Several studies have shown that dexmedetomidine has an anesthetic sparing effect, which has led to its use as a general adjuvant for prolonging peripheral nerve block duration.
A crosslinked cation exchange polymer for use in removing potassium from the gastrointestinal (GI) tract of an animal subject, the crosslinked cation exchange polymer comprising acid groups in acid or salt form, the polymer being in the form of substantially spherical particles having a mean diameter of from 20 microns to 200 microns and less than 4 volume percent of the particles have a diameter of less than 10 microns, and the polymer having a sediment yield stress of less than about 4000 Pa, and a swelling ratio of less than 10 grams of water per gram of polymer. Alternatively, the same crosslinked cation exchange polymer is in the form of substantially spherical particles having a mean diameter of less than 250 microns and less than 4 volume percent of the particles having a diameter of less than 10 microns, and the polymer has a swelling ratio of less than 10 grams of water per gram of polymer, and a hydrated and sedimented mass of polymer particles has a viscosity of less than 1,000,000 Pa, the viscosity being measured at a shear rate of 0.01 sec-1. The preferred polymer to be crosslinked is poly(Î±-fluoroacrylic acid) in salt form. The preferred crosslinking agent is divinylbenzene (DVB). The crosslinked cation exchange polymers have beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio. The polymers may be formulated into pharmaceutical compositions, such as with a linear polyol, especially sorbitol and/or xylitol. These polymers and/or compositions bind to potassium in the GI tract, and are thus are particularly useful for the treatment of hyperkalemia.
The invention relates to a microorganism multienzyme additive for promoting the growth and development of baby pigs, which is characterized in that the additive is formed by composite synchronizing solid fermentation of a composite strain stock solution, carbon source, nitrogen source, inorganic salt and enzyme revulsant. A manufacturing method is that all the strains adopt a composite inducing technology to carry through filtering; a method of synchronizing liquid culture and solid composite culture is adopted to lead all the strains to be cultivated in the same culture medium; the total number of live bacterium reaches 3 billion/g and simultaneously a fermented product is kept completely. The product comprises massive physiological metabolism substances like active enzyme, small peptide, oxidation resistance substances, FAA, vitamins, etc. A specific type for feed preparing particles carries through a double-layer microcapsule peridium treatment on the strains that can not resist heat. The invention has the advantages of promoting the digestive absorption on the feed by the baby pigs, promoting the compound of organism protein and full utilization, increasing the disease resistance and immunological competence of the baby pigs, improving the feed switching rate and the production capacity of cultivated animals, reducing the pollution to the environment caused by animal dejecta. The invention is a green and safe agrotechnical product.
Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
Pre-clinical and clinical studies suggest a role for inflammation in the pathophysiology of cardiovascular (CV) diseases. The NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is activated during tissue injury and releases interleukin-1β (IL-1β). We describe three paradigms in which the NLRP3 inflammasome and IL-1β contribute to CV diseases. During acute myocardial infarction (AMI), necrotic cell debris, including IL-1α, induce NLRP3 inflammasome activation and further damage the myocardium contributing to heart failure (HF) (acute injury paradigm). In chronic HF, IL-1β is induced by persistent myocardial overload and injury, neurohumoral activation and systemic comorbidities favoring infiltration and activation of immune cells into the myocardium, microvascular inflammation, and a pro-fibrotic response (chronic inflammation paradigm). In recurrent pericarditis, an autoinflammatory response triggered by cell injury and maintained by the NLRP3 inflammasome/IL-1β axis is present (autoinflammatory disease paradigm). Anakinra, recombinant IL-1 receptor antagonist, inhibits the acute inflammatory response in patients with ST elevation myocardial infarction (STEMI) and acute HF. Canakinumab, IL-1β antibody, blunts systemic inflammation and prevents complications of atherosclerosis in stable patients with prior AMI. In chronic HF, anakinra reduces systemic inflammation and improves cardiorespiratory fitness. In recurrent pericarditis, anakinra and rilonacept, a soluble IL-1 receptor chimeric fusion protein blocking IL-1α and IL-1β, treat and prevent acute flares. In conclusion, the NLRP3 inflammasome and IL-1 contribute to the pathophysiology of CV diseases, and IL-1 blockade is beneficial with different roles in the acute injury, chronic inflammation and autoinflammatory disease paradigms. Further research is needed to guide the optimal use of IL-1 blockers in clinical practice.
Most theories of pain emphasize cognitive factors in the development of chronicity, but they have rarely been studied in the context of the transition from acute to chronic pain. The aim of the present study was to assess the role of interpretation bias, pain anxiety, and pain avoidance in acute and chronic pain and the transition from acute to chronic pain. Study 1 recruited a sample of N = 85 adults with chronic pain. Study 2 recruited a sample of N = 254 adults with acute pain and followed them up 3 months later. Both studies assessed interpretation bias with the word association task, as well as measuring pain-related anxiety, pain avoidance, pain severity, and pain interference. In study 2, pain outcomes at 3 months were also assessed. Across both acute and chronic pain samples, interpretation bias was associated with pain interference, but not pain severity. Path analysis mediation models for study 2 showed that interpretation bias was associated with increased pain anxiety, which predicted both pain severity and pain interference 3 months later. Pain anxiety was also associated with pain avoidance, but pain avoidance did not predict pain outcomes. This research provides further insight into the transition from acute to chronic pain, suggesting that interpretation bias in acute pain may play a role in pain-related anxiety that drives pain interference, thus maintaining chronic pain. These findings hold promise for further research into potential large-scale preventative interventions targeting interpretation bias and pain anxiety in acute pain.
PURPOSE:A base composition for biological electrode of iontophoresis making endermic absorption of generalized drug possible at low current density, containing a pyrrolidonecarboxylic acid derivative as an essential component. CONSTITUTION:The titled composition containing a pyrrolidone-carboxylic acid derivative shown by formula (R1 is H or <=5C aliphatic hydrocarbon; R2 is 7-20C aliphatic hydrocarbon) as an essential component. Iontophoresis is electrical therapy by DC electric current, a method wherein a drug is permeated into the skin by the use of polar effect on ionized molecules. When a generalized drug is administered by the use of the base composition by iontophoresis, since permeation of the ionic drug to the skin is synergistically promoted, ion introduc tion is made possible even at low electric current. Since the composition can be administered for a long period, medicinal effect can be prolonged. The compo sition contains an organic solvent and/or water and its blending ratio is 5-60:25-95:0-60(wt%).
The method involves receiving or generating data in a form of medical image data (B). The data is assigned to fixed dimension groups (GK1-GK4, GKD) that represent memory space consumption. The dimension groups are determined by configuration rules that are referred on a selected attribute e.g. digital imaging and communications in medicineattribute of the received or generated data, such that the dimension groups form the homogeneous memory space consumption. The data is provided with a patient-test requested data that is triggered by a radiology information system. An independent claim is also included for a medical-computer system comprising a receiving unit.
BACKGROUND/OBJECTIVES: Childhood obesity, particularly in girls, is linked to early puberty onset, heightening risks for adult-onset diseases. Addressing childhood obesity and precocious puberty is vital to mitigate societal burdens. Despite existing costly and invasive medical interventions, introducing lifestyle-based alternatives is essential. Our study investigates alternate-day fasting's (ADF) impact on pubertal development in normal-weight and high-fat diet (HFD)-induced obese female mice.
METHODS: Four groups of female mice were utilized, with dams initially fed control chow during and before pregnancy. Post-parturition, two groups continued on control chow, while two switched to an HFD. Offspring diets mirrored maternal exposure. One control and one HFD group were subjected to ADF. Morphometry and hormone analyses at various time points were performed.
RESULTS: Our findings demonstrate that ADF in normal-weight mice led to reduced body length, weight, uterine, and ovarian weights, accompanied by delayed puberty and lower levels of sex hormones and growth hormone (GH). Remarkably, GH treatment effectively prevented ADF-induced growth reduction but did not prevent delayed puberty. Conversely, an HFD increased body length, induced obesity and precocious puberty, and altered sex hormones and leptin levels, which were counteracted by ADF regimen. Our data indicate ADF's potential in managing childhood obesity and precocious puberty.
CONCLUSIONS: ADF reduced GH and sex hormone levels, contributing to reduced growth and delayed puberty, respectively. Therefore, parents of normal-weight children should be cautious about prolonged overnight fasting. ADF prevented HFD-induced obesity and precocious puberty, offering an alternative to medical approaches; nevertheless, further studies are needed for translation into clinical practice.
Persistent and unrelenting stress is defined as anxiety. Anxiety disorders are among the most common mental disorders in society. The NIH estimates that nearly 200 million Americans suffer from anxiety. Anxiety disorders are associated with a lower quality of life, functional impairment and disability, and are also associated with co-morbid physical illness.

Acupuncture, one form of complementary and alternative medicine, has been used to treat anxiety. Non-needle acupuncture is one of the safest methods, with none to rare side effects. This method has been studied in China (Han 1986) and America (Ulett 1998) Pre-intervention testing, then three treatments within one week, will be followed by post intervention testing.
Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by "sonic oscillator"' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under "detailed description".
PURPOSE: Nasopharyngeal carcinoma (NPC) is an aggressive head and neck disease with a high incidence of distant metastases. Enlargeosomes are cytoplasmic organelles marked by, desmoyokin/AHNAK. This study aimed to evaluate the expression of AHNAK in NPC and its effect on enlargeosomes and to investigate the correlation between AHNAK expression levels and clinical NPC patient characteristics.
METHODS: Primary nasopharyngeal carcinoma (NPC) and NPC specimens were evaluated by analyzing public data, and immunohistochemistry. Systematic in vitro and in vivo experiments were performed using different NPC-derived cell lines and mouse models.
RESULTS: In this study, we detected AHNAK and Annexin A2(ANXA2), a protein coating the surface of enlargeosomes, in NPC samples. We found that AHNAK was down-regulated. Down-regulation of AHNAK was associated with poor overall survival in NPC patients. Moreover, transcription factor FOSL1-mediated transcriptional repression was responsible for the low expression of AHNAK by recruiting EZH2. Whereas Annexin A2 was upregulated in human NPC tissues. Upregulation of Annexin A2 was associated with lymph node metastasis and distant metastasis in NPC patients. Functional studies confirmed that silencing of AHNAK enhanced the growth, invasion, and metastatic properties of NPC cells both in vitro and in vivo. In terms of mechanism, loss of AHNAK led to an increase of annexin A2 protein level in NPC cells. Silencing ANXA2 restored NPC cells' migrative and invasive ability upon loss of AHNAK.
CONCLUSION: Here, we report AHNAK as a tumor suppressor in NPC, which may act through annexin A2 oncogenic signaling in enlargeosome, with potential implications for novel approaches to NPC treatment.
This study will compare the structure, chemical composition and other characteristics of skin and blood in people with and without parasitic infections. Cell samples will be taken from blisters produced by suction blistering. This study may provide new information about the interactions between parasites and the immune system that could lead to better treatments for these infections.

Normal volunteers and patients with acute helminth (a type of parasite) infections aged 18 years older may be eligible for this study. Following a medical history and physical exam, participants will undergo suction blistering to provide cells needed for study. A suction blister device is attached to the skin of the thigh. A heating element in the device heats the skin to speed blister formation. (This will feel only a slightly warm.) The device is removed after about two hours, when the blisters have formed. The blister tops are removed with sterile scissors. The blistered areas are then treated with special dressings to promote healing and the participant is discharged with further wound care instructions. A small amount of blood (around four tablespoons) may be drawn to compare chemicals in the blood with chemicals in the blister fluid. Participants will be contacted by telephone over the next 72 hours to check on healing. Further follow-up will occur by phone at 6 months and 1 year.

Up to 60 blisters may be produced over a one-year period (in three separate sessions every six months) with no more than 20 raised per session.